Three years af­ter sell­ing Ac­er­ta to As­traZeneca in $7B deal, Dave John­son is back at the helm of a biotech start­up

Three years ago Dave John­son steered Ac­er­ta to a $7 bil­lion buy­out deal with As­traZeneca, set­ting up a rel­a­tive­ly quick­ly tran­si­tion of acal­abru­ti­nib in­to the on­col­o­gy mar­ket, where it’s now sold as Calquence.

Now, John­son is back at the helm of a new biotech start­up, and he’s still in­ter­est­ed in do­ing some­thing new in the siz­zling can­cer R&D field — this time fo­cus­ing on an­ti­body-drug con­ju­gates. John­son has a $58 mil­lion A round to get start­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER